Harnessing artificial intelligence for prostate cancer management

Lingxuan Zhu¹, Jiahua Pan², Weiming Mou³, Longxin Deng⁴, Yinjie Zhu², Yanqing Wang², Gyan Pareek⁵, Elias Hyams⁵, Benedito A Carneiro⁶, Matthew J Hadfield⁶, Wafik S El-Deiry⁷, Tao Yang⁸, Tao Tan⁹, Tong Tong¹⁰, Na Ta¹¹, Yan Zhu¹¹, Yisha Gao¹¹, Yancheng Lai¹², Liang Cheng¹³, Rui Chen¹⁴, Wei Xue¹⁵

Affiliations

¹ Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China; Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Changping Laboratory, Beijing, China.
² Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
³ Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁴ Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
⁵ Department of Surgery (Urology), Brown University Warren Alpert Medical School, Providence, RI, USA; Minimally Invasive Urology Institute, Providence, RI, USA.
⁶ The Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI, USA.
⁷ The Legorreta Cancer Center at Brown University, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Pathology & Laboratory Medicine, The Warren Alpert Medical School of Brown University, The Joint Program in Cancer Biology, Brown University and Lifespan Health System, Division of Hematology/Oncology, The Warren Alpert Medical School of Brown University, Providence, RI, USA.
⁸ Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
⁹ Faculty of Applied Sciences, Macao Polytechnic University, Address: R. de Luís Gonzaga Gomes, Macao, China.
¹⁰ College of Physics and Information Engineering, Fuzhou University, Fujian 350108, China.
¹¹ Department of Pathology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
¹² Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China; The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
¹³ Department of Surgery (Urology), Brown University Warren Alpert Medical School, Providence, RI, USA; Department of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, Lifespan Health, and the Legorreta Cancer Center at Brown University, Providence, RI, USA. Electronic address: liang_cheng@yahoo.com.
¹⁴ Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China. Electronic address: drchenrui@foxmail.com.
¹⁵ Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China. Electronic address: uroxuewei@163.com.

PMID: 38593808
PMCID: PMC11031422
DOI: 10.1016/j.xcrm.2024.101506

Review

Harnessing artificial intelligence for prostate cancer management

Lingxuan Zhu et al. Cell Rep Med. 2024.

. 2024 Apr 16;5(4):101506.

doi: 10.1016/j.xcrm.2024.101506. Epub 2024 Apr 8.

Authors

Affiliations

¹ Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China; Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Changping Laboratory, Beijing, China.
² Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
³ Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁴ Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
⁵ Department of Surgery (Urology), Brown University Warren Alpert Medical School, Providence, RI, USA; Minimally Invasive Urology Institute, Providence, RI, USA.
⁶ The Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI, USA.
⁷ The Legorreta Cancer Center at Brown University, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Pathology & Laboratory Medicine, The Warren Alpert Medical School of Brown University, The Joint Program in Cancer Biology, Brown University and Lifespan Health System, Division of Hematology/Oncology, The Warren Alpert Medical School of Brown University, Providence, RI, USA.
⁸ Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
⁹ Faculty of Applied Sciences, Macao Polytechnic University, Address: R. de Luís Gonzaga Gomes, Macao, China.
¹⁰ College of Physics and Information Engineering, Fuzhou University, Fujian 350108, China.
¹¹ Department of Pathology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
¹² Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China; The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
¹³ Department of Surgery (Urology), Brown University Warren Alpert Medical School, Providence, RI, USA; Department of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, Lifespan Health, and the Legorreta Cancer Center at Brown University, Providence, RI, USA. Electronic address: liang_cheng@yahoo.com.
¹⁴ Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China. Electronic address: drchenrui@foxmail.com.
¹⁵ Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China. Electronic address: uroxuewei@163.com.

PMID: 38593808
PMCID: PMC11031422
DOI: 10.1016/j.xcrm.2024.101506

Abstract

Prostate cancer (PCa) is a common malignancy in males. The pathology review of PCa is crucial for clinical decision-making, but traditional pathology review is labor intensive and subjective to some extent. Digital pathology and whole-slide imaging enable the application of artificial intelligence (AI) in pathology. This review highlights the success of AI in detecting and grading PCa, predicting patient outcomes, and identifying molecular subtypes. We propose that AI-based methods could collaborate with pathologists to reduce workload and assist clinicians in formulating treatment recommendations. We also introduce the general process and challenges in developing AI pathology models for PCa. Importantly, we summarize publicly available datasets and open-source codes to facilitate the utilization of existing data and the comparison of the performance of different models to improve future studies.

Keywords: artificial intelligence; machine learning; pathology; prostate cancer; whole-slide image.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Figures

**Figure 1**
The development process of pathology AI models, using automated Gleason grading as an example

**Figure 2**
Interaction between pathology AI models and pathologists

See this image and copyright information in PMC

References

1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
1. Han W., Johnson C., Gaed M., Gómez J.A., Moussa M., Chin J.L., Pautler S., Bauman G.S., Ward A.D. Histologic tissue components provide major cues for machine learning-based prostate cancer detection and grading on prostatectomy specimens. Sci. Rep. 2020;10:9911. doi: 10.1038/s41598-020-66849-2. - DOI - PMC - PubMed
1. Eichler K., Hempel S., Wilby J., Myers L., Bachmann L.M., Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J. Urol. 2006;175:1605–1612. doi: 10.1016/S0022-5347(05)00957-2. - DOI - PubMed
1. Cheng L., MacLennan G.T., Bostwick D.G. Fourth edition. Elsevier; 2020. Urologic Surgical Pathology.
1. Ozkan T.A., Eruyar A.T., Cebeci O.O., Memik O., Ozcan L., Kuskonmaz I. Interobserver variability in Gleason histological grading of prostate cancer. Scand. J. Urol. 2016;50:420–424. doi: 10.1080/21681805.2016.1206619. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Harnessing artificial intelligence for prostate cancer management

Affiliations

Harnessing artificial intelligence for prostate cancer management

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical